AAREY DRUGS & PHARMACEUTICALS
|
|
BOM : 524412     NSE : AAREYDRUGS     | |
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Mild Upward Pledged Shares : NA |
Jul 26,2024 |
Price(EOD): ₹ 50.37
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 141.54 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
AAREY DRUGS & PHARMACEUTICALS | 2.8% | 7.2% | 53.7% |
SUN PHARMACEUTICAL INDUSTRIES | 7.9% | 12.6% | 51.7% |
CIPLA | 5.9% | 6.7% | 43% |
DR REDDYS LABORATORIES | 1.8% | 13.6% | 29.6% |
ZYDUS LIFESCIENCES | 4.5% | 13.1% | 96.6% |
DIVIS LABORATORIES | 5.7% | 5.5% | 23.4% |
MANKIND PHARMA | -2.5% | -3.8% | 12.9% |
TORRENT PHARMACEUTICALS | 5.4% | 14.3% | 59.2% |
LUPIN | 1.9% | 16.1% | 92.7% |
FUNDAMENTAL ANALYSIS OF AAREY DRUGS & PHARMACEUTICALS
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF AAREY DRUGS & PHARMACEUTICALS
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
25.38
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 5.57 Cr
[Latest Qtr - Mar2024 - Standalone Results ] 1.23
P/B Calculated based on Book Value of Rs 115.09 Cr
[Latest Year - Mar2023 - Standalone Results ] 0.36
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Mar2024 - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
856% 254% 171% |
SHARE PRICE MOMENTUM OF AAREY DRUGS & PHARMACEUTICALS
AAREY DRUGS & PHARMACEUTICALS vs SENSEX
DEBT OF AAREY DRUGS & PHARMACEUTICALS
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2023 2022 2021 Avg_3yrs |
0.33 0.13 0.19 0.22 |
- - - - |
[Last Annual Data : Mar2023]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF AAREY DRUGS & PHARMACEUTICALS
Pledged Promoter Shares |
NA | |
---|---|---|
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF AAREY DRUGS & PHARMACEUTICALS
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
175.06% -153.26% 46.52% 12.8% |
32.98% 33.93% NA 494.2% |
QtrlyTrend |
5 | |
Latest Qtr: Mar2024 | ||
Quarterly Result Analysis → |
AAREY DRUGS & PHARMACEUTICALS related INDICES
You may also like the below Video Courses
FAQ about AAREY DRUGS & PHARMACEUTICALS
Is AAREY DRUGS & PHARMACEUTICALS good for long term investment?
As on Jul 26,2024, the Fundamentals of AAREY DRUGS & PHARMACEUTICALS look Poor and hence it may not be good for long term investment ! See Financial Performance of AAREY DRUGS & PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is AAREY DRUGS & PHARMACEUTICALS UnderValued or OverValued?
As on Jul 26,2024, AAREY DRUGS & PHARMACEUTICALS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of AAREY DRUGS & PHARMACEUTICALS ?
As on Jul 26,2024, the Intrinsic Value of AAREY DRUGS & PHARMACEUTICALS is Rs. 14.22 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 5.27
Fair Value [Median EV / Sales Model] : Rs. 14.22
Fair Value [Median Price / Sales Model] : Rs. 18.61
Estimated Median Fair Value of AAREY DRUGS & PHARMACEUTICALS : Rs. 14.22
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.